$256.06
1.01% day before yesterday
NYSE, Oct 03, 10:00 pm CET

Penumbra, Inc. Stock price

$256.06
-13.65 5.06% 1M
-17.18 6.29% 6M
+18.58 7.82% YTD
+61.07 31.32% 1Y
+60.49 30.93% 3Y
+66.06 34.77% 5Y
+216.18 542.08% 10Y
+214.76 520.00% 20Y
NYSE, Closing price Fri, Oct 03 2025
+2.57 1.01%

Key metrics

Basic
Market capitalization
$10.0b
Enterprise Value
$9.6b
Net debt
positive
Cash
$424.6m
Shares outstanding
39.0m
Valuation (TTM | estimate)
P/E
68.1 | 68.0
P/S
7.8 | 7.2
EV/Sales
7.5 | 6.9
EV/FCF
59.3
P/B
7.7
Financial Health
Equity Ratio
75.1%
Return on Equity
1.2%
ROCE
10.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.3b | $1.4b
EBITDA
$159.8m | $236.9m
EBIT
$159.3m | $184.1m
Net Income
$147.7m | $146.8m
Free Cash Flow
$161.6m
Growth (TTM | estimate)
Revenue
12.9% | 15.5%
EBITDA
36.3% | 159.2%
EBIT
48.5% | 113.5%
Net Income
938.7% | 947.5%
Free Cash Flow
46.0%
Margin (TTM | estimate)
Gross
66.5%
EBITDA
12.5% | 17.2%
EBIT
12.5%
Net
11.5% | 10.6%
Free Cash Flow
12.6%
More
EPS
$3.8
FCF per Share
$4.1
Short interest
7.1%
Employees
5k
Rev per Employee
$270.0k
Show more

Is Penumbra, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Penumbra, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Penumbra, Inc. forecast:

19x Buy
79%
5x Hold
21%

Analyst Opinions

24 Analysts have issued a Penumbra, Inc. forecast:

Buy
79%
Hold
21%

Financial data from Penumbra, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,280 1,280
13% 13%
100%
- Direct Costs 429 429
10% 10%
34%
851 851
15% 15%
66%
- Selling and Administrative Expenses 601 601
13% 13%
47%
- Research and Development Expense 91 91
2% 2%
7%
160 160
36% 36%
12%
- Depreciation and Amortization 0.43 0.43
96% 96%
0%
EBIT (Operating Income) EBIT 159 159
49% 49%
12%
Net Profit 148 148
939% 939%
12%

In millions USD.

Don't miss a Thing! We will send you all news about Penumbra, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Penumbra, Inc. Stock News

Neutral
Seeking Alpha
25 days ago
Penumbra, Inc. (NYSE:PEN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Welcome, everyone. Patrick on the Medtech team.
Neutral
PRNewsWire
26 days ago
Survey Conducted by the Get Out the Clot Campaign, an Initiative Focused on Identifying and Closing Gaps in Patient Care for Blood Clots ALAMEDA, Calif. , Sept. 9, 2025 /PRNewswire/ -- The American Venous Forum (AVF), International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra (NYSE: PEN), The PERT Consortium® and Society for Vascular Medicine (SVM)...
Neutral
Seeking Alpha
about one month ago
Penumbra, Inc. (NYSE:PEN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:45 AM EDT Company Participants Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Good morning, eve...
More Penumbra, Inc. News

Company Profile

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Head office United States
CEO Adam Elsesser
Employees 4,500
Founded 2004
Website www.penumbrainc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today